We unleash insight, innovation and agility to transform lives by advancing the products and business of cancer care.

LEARN MORE ABOUT CHURCHILL PHARMACEUTICALS

Improving oral oncolytics through SoluMatrix® Fine Particle Technology™

LEARN MORE ABOUTSOLUTMATRIX® TECHNOLOGY

Leveraging SoluMatrix® Fine Particle Technology™ to develop needed therapies for patients living with genitourinary cancer

LEARN MORE ABOUT OUR PIPELINE
Next
Prev
Arrow Down

Bringing value to cancer care

Churchill Pharmaceuticals brings true value to cancer care.

We provide quality, orally delivered oncology products with optimized clinical profiles including enhanced efficacy, safety and efficiency. Our commitment to responsibly deliver these advantages to the patients, payers, and healthcare communities we serve is at the core of our business.

LEARN MORE ABOUT CHURCHILL
value Care

About Us

The Churchill team pairs depth-of-experience with an agile, entrepreneurial approach to responsibly bring forward improved oral oncology products.

LEARN MORE ABOUT CHURCHILL

Pipeline

Leveraging SoluMatrix® Fine Particle Technology™ to develop needed therapies for patients living with genitourinary cancer.

view our PIPELINE

Technology

Improving oral oncolytics through SoluMatrix® Fine Particle Technology™

VIEW OUR TECHNOLOGY

Latest Media

Churchill Pharmaceuticals Announces NDA Filing Acceptance for YONSA™ by the U.S. FDA

KING OF PRUSSIA, Pa., July 20, 2017 /PRNewswire/ -- Churchill Pharmaceuticals, LLC (Churchill), a privately held company devoted to expanding treatment options...
July 20, 2017

Impact of an alternative steroid on the relative bioavailability and bioequivalence of a novel versus the originator formulation of abiraterone acetate

Click here to view the article.
July 10, 2017

Churchill Pharmaceuticals Expands Commercial Leadership Team

King of Prussia, PA., May 30, 2017 Churchill Pharmaceuticals, LLC (Churchill), a clinical-stage biopharmaceutical company, today announced the expansion of...
May 30, 2017